Syndrome News and Research

RSS

UB researchers to investigate influence of environmental factors on MS progression

A $634,000 grant from the Department of Defense is allowing researchers at the University at Buffalo to investigate a trio of environmental factors and their influence on the progression of multiple sclerosis.

23 Sep 2010

Scientists identify genetic variants that increase asthma susceptibility

An international study looking at DNA from over 26,000 people has identified several genetic variants that substantially increase susceptibility to asthma in the population. The findings, published in the New England Journal of Medicine, will help scientists to focus their efforts to develop better therapies for the illness.

23 Sep 2010

First intestine transplant in Michigan performed on 50-year-old Port Austin patient

The first intestine (bowel) transplant in Michigan was performed on a 50-year-old patient from Port Austin by physicians at Henry Ford Hospital.

23 Sep 2010

AstraZeneca to use THEW database for cardiac safety evaluation

AstraZeneca purchased a one-year membership to gain access to an international repository of data designed to aid industry and academic researchers developing new technologies to improve cardiac safety.

23 Sep 2010

Researchers receive $634,000 grant to study environmental factors, MS progression

22 Sep 2010

Pancreas releases new NANETS guidelines on rare group of cancers

Neuroendocrine tumors (NETs) are a group of rare cancers that pose unique challenges in diagnosis and treatment. In a recent issue of Pancreas, official journal of the American Pancreatic Association, presents the newly developed consensus guidelines of the North American Neuroendocrine Tumor Society (NANETS).

22 Sep 2010

FDA guides Apricus Bio on RayVa's approvability for Raynaud's syndrome secondary to scleroderma

Apricus Biosciences, backed by a revenue-generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, announced today that the U.S. Food and Drug Administration (FDA) has provided guidance on the clinical requirements for assessing the approvability of RayVa for the treatment of Raynaud's syndrome secondary to scleroderma.

22 Sep 2010

Specific orofacial characteristics can lead to accurate diagnosis of fetal alcohol spectrum disorders

Fetal alcohol spectrum disorders (FASD) is an umbrella term that describes the range of effects that can occur in a person whose mother drank alcohol while pregnant. Each year, FASD affect an estimated 40,000 infants in the United States—more than spina bifida, Down syndrome, and muscular dystrophy combined.

22 Sep 2010

QR Pharma and MUSC receive $220,000 SBIR grant to study Posiphen in AD transgenic mice

QR Pharma, Inc., a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment and Alzheimer's disease and the Medical University of South Carolina (MUSC) announced today that they received a Small Business Innovation Research (SBIR) phase I grant in the amount of $220,000 to study Posiphen® and its metabolites in cell culture and in transgenic Alzheimer mice.

22 Sep 2010

FDA grants orphan-drug designation to Catalyst's CPP-115 investigational drug

Catalyst Pharmaceutical Partners, Inc. today announced that its investigational drug, CPP-115, a novel GABA aminotransferase inhibitor, has been granted orphan-drug designation for the treatment of infantile spasms (West Syndrome) by the U.S. Food and Drug Administration (FDA).

22 Sep 2010

FDA grants Phadia 510(k) clearance for CLIA Moderate Complexity, EliA autoimmune antibody assays

Today Phadia announced that it has received FDA 510(k) clearance for two new, CLIA Moderate Complexity, EliA autoimmune antibody assays. The new assays will provide physicians with additional tools needed to aid in the diagnosis of Celiac disease. The newly available assays, EliA GliadinDP IgA and EliA GliadinDP IgG (deamidated peptides), have proven to be essential, sensitive and specific markers to aid in the diagnosis of celiac disease.

22 Sep 2010

High dose aspirin effective for treatment of severe headache and migraine

An inexpensive, hundred-year-old therapy for pain - aspirin - is effective in high doses for the treatment of severe headache and migraine caused by drug withdrawal, according to a new study by researchers with the UCSF Headache Center. Study participants were administered aspirin through an IV and 25 percent of the time they reported a significant reduction in pain - three points on the 10-point pain scale.

22 Sep 2010

Celera receives patent on KIF6 gene variant

Celera Corporation today announced that the United States Patent and Trademark Office has issued United States Patent 7,799,530 relating to methods of determining heart attack risk by detecting the KIF6 gene variant and reduction of such increased risk by statin therapy.

21 Sep 2010

Oxy-Powder supplement clears clinical trials for Irritable Bowel Syndrome

The popular nutraceutical health supplement, Oxy-Powder has passed clinical trials for Irritable Bowel Syndrome (IBS) with a 99.9 percent success rate.According to the NIH, approximately 20% of Americans suffer from the symptoms of IBS, which qualifies it as one of the most common medical problems in the United States.

21 Sep 2010

Annals of Internal Medicine publishes GRACE study data on HIV therapy

Data from the GRACE study will be published in the September 21st issue of the Annals of Internal Medicine. GRACE is the largest-ever study of treatment experienced adult women with HIV-1 to examine gender differences in response to HIV therapy. Sponsored by Tibotec Therapeutics Clinical Affairs, a division of Centocor Ortho Biotech Services, LLC, the GRACE study enrolled 67 percent women, demonstrating that it is possible to recruit large numbers of women into U.S.-based HIV treatment studies.

21 Sep 2010

H1N1 influenza increases neurological complications in children: Study

A recent study by researchers at the University of Utah determined that the 2009 pandemic influenza A (H1N1) caused a higher rate of neurological complications in children than the seasonal flu. The most common complications observed were seizures and encephalopathy.

20 Sep 2010

Penn study reveals structure of cell division's key molecule

On average, one hundred billion cells in the human body divide over the course of a day. Most of the time the body gets it right but sometimes, problems in cell replication can lead to abnormalities in chromosomes resulting in many types of disorders, from cancer to Down Syndrome.

18 Sep 2010

Atherotech Diagnostics publishes article on advantages of cholesterol testing

Detailed cholesterol testing for Type 2 diabetes patients is the focus of a newly published article by Atherotech Diagnostics Lab Chief Medical Officer Michael E. Cobble, M.D. The article discusses the clinical advantages of advanced cholesterol testing in reducing cardiovascular disease (CVD) risk in patients with Type 2 diabetes and details several currently available advanced lipid tests, including the VAP® Cholesterol Test from Atherotech.

18 Sep 2010

Research on signaling pathways may help to design therapy for neurodevelopmental disorders

Researchers at the Center for Neuroscience Research at Children's National Medical Center have discovered that the two major types of signaling pathways activated during brain cell development-the epidermal growth factor receptor pathway and the Notch pathway-operate together to determine how many and which types of brain cells are created during growth and repair in developing and adult brains.

17 Sep 2010

Metabolic Solutions to present MSDC-0160 clinical candidate data at EASD conference

Metabolic Solutions Development Company (MSDC), will present research at the European Association for the Study of Diabetes (EASD) annual conference in Stockholm, Sweden on Sept. 23, 2010. The research indicates that the company's clinical candidate, MSDC-0160, promotes the proliferation of stem cells that create brown fat, leading to the creation of more brown fat. The research was conducted in tissue cultures and mice.

17 Sep 2010

Syndrome News and Research

UB researchers to investigate influence of environmental factors on MS progression

Scientists identify genetic variants that increase asthma susceptibility

First intestine transplant in Michigan performed on 50-year-old Port Austin patient

AstraZeneca to use THEW database for cardiac safety evaluation

Researchers receive $634,000 grant to study environmental factors, MS progression

Pancreas releases new NANETS guidelines on rare group of cancers

FDA guides Apricus Bio on RayVa's approvability for Raynaud's syndrome secondary to scleroderma

Specific orofacial characteristics can lead to accurate diagnosis of fetal alcohol spectrum disorders

QR Pharma and MUSC receive $220,000 SBIR grant to study Posiphen in AD transgenic mice

FDA grants orphan-drug designation to Catalyst's CPP-115 investigational drug

FDA grants Phadia 510(k) clearance for CLIA Moderate Complexity, EliA autoimmune antibody assays

High dose aspirin effective for treatment of severe headache and migraine

Celera receives patent on KIF6 gene variant

Oxy-Powder supplement clears clinical trials for Irritable Bowel Syndrome

Annals of Internal Medicine publishes GRACE study data on HIV therapy

H1N1 influenza increases neurological complications in children: Study

Penn study reveals structure of cell division's key molecule

Atherotech Diagnostics publishes article on advantages of cholesterol testing

Research on signaling pathways may help to design therapy for neurodevelopmental disorders

Metabolic Solutions to present MSDC-0160 clinical candidate data at EASD conference

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News